Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas.

Joshua L WangRolf F BarthRobert CavaliereVinay K PuduvalliPierre GiglioRussell R LonserJ Bradley Elder

Published in: PloS one (2020)

IC CED of carboplatin as a potential therapy for recurrent malignant glioma is feasible and safe at doses up to 4μg in 54mL over 72 hours. Further studies are needed to determine the maximum tolerated dose and potential efficacy.

Keyphrases

high grade
phase iii
low grade
clinical trial
human health
squamous cell carcinoma
phase ii
open label
rectal cancer
locally advanced
placebo controlled